Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program

Core Insights - Eyenovia has acquired a significant position in HYPE tokens, making it the first Nasdaq-listed company to operate a validator on the Hyperliquid blockchain [1][2] - The company has successfully closed a $50 million private placement (PIPE) to fund the acquisition of 1,040,584.5 HYPE tokens at an average price of approximately $34 per token [2][3] - Eyenovia is on track for FDA registration of its Optejet User Filled Device (UFD) by September 2025, with ongoing discussions for potential partnerships [1][5] Company Strategy - The acquisition of HYPE tokens is part of Eyenovia's new cryptocurrency treasury reserve strategy aimed at creating long-term shareholder value through digital currency adoption [3] - The company plans to initiate its own network validator to support the Hyperliquid blockchain and access HYPE staking yield [2][3] - Eyenovia is expected to change its name and ticker to "Hyperion DeFi" and "HYPD" pending Board approval [4] Product Development - Development of the Optejet UFD is progressing as planned, with verification and validation activities set to begin next month [5] - The Optejet is designed for various topical ophthalmic liquids, enhancing treatment compliance and outcomes for patients with chronic front-of-the-eye diseases [9] Hyperliquid Platform Overview - Hyperliquid is a layer one blockchain optimized for high-frequency trading, featuring on-chain perpetual futures and spot order books [6] - HYPE, the native token of Hyperliquid, provides utility through reduced trading fees and increased referral bonuses, with over 25 million HYPE sequestered by the blockchain as of June 2025 [7]